Zevra Therapeutics (NASDAQ:ZVRA) CEO Neil Mcfarlane Sells 20,000 Shares of Company Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil Mcfarlane sold 20,000 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $11.25, for a total value of $225,000.00. Following the sale, the chief executive officer directly owned 417,225 shares in the company, valued at approximately $4,693,781.25. This represents a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zevra Therapeutics Stock Down 8.2%

Shares of Zevra Therapeutics stock opened at $10.39 on Wednesday. The company has a market capitalization of $616.96 million, a price-to-earnings ratio of 7.16 and a beta of 0.98. The stock’s 50-day simple moving average is $11.54 and its 200-day simple moving average is $11.41. Zevra Therapeutics, Inc. has a 52 week low of $8.01 and a 52 week high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. On average, equities analysts expect that Zevra Therapeutics, Inc. will post 0.72 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, July 27th. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Citizens Jmp boosted their target price on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, August 6th. UBS Group reissued a “buy” rating on shares of Zevra Therapeutics in a report on Thursday, August 20th. Finally, William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and a consensus target price of $27.14.

Institutional Investors Weigh In On Zevra Therapeutics

Large investors have recently made changes to their positions in the company. AIGH Capital Management LLC purchased a new position in Zevra Therapeutics during the 1st quarter valued at approximately $11,184,000. Bank of New York Mellon Corp bought a new stake in Zevra Therapeutics in the 2nd quarter worth approximately $2,846,000. Dimensional Fund Advisors LP increased its stake in Zevra Therapeutics by 259.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after acquiring an additional 400,336 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Zevra Therapeutics by 116.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after acquiring an additional 206,543 shares in the last quarter. Finally, Globeflex Capital L P purchased a new stake in shares of Zevra Therapeutics during the 2nd quarter worth approximately $2,752,000. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.